[go: up one dir, main page]

SG10201506658TA - Utility of b-raf dna mutation in diagnosis and treatment of cancer - Google Patents

Utility of b-raf dna mutation in diagnosis and treatment of cancer

Info

Publication number
SG10201506658TA
SG10201506658TA SG10201506658TA SG10201506658TA SG10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA SG 10201506658T A SG10201506658T A SG 10201506658TA
Authority
SG
Singapore
Prior art keywords
diagnosis
cancer
treatment
utility
dna mutation
Prior art date
Application number
SG10201506658TA
Inventor
Dave S B Hoon
Original Assignee
Wayne John Cancer Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst filed Critical Wayne John Cancer Inst
Publication of SG10201506658TA publication Critical patent/SG10201506658TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG10201506658TA 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer SG10201506658TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89158907P 2007-02-26 2007-02-26
US89324307P 2007-03-06 2007-03-06

Publications (1)

Publication Number Publication Date
SG10201506658TA true SG10201506658TA (en) 2015-09-29

Family

ID=39721826

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012012647A SG178814A1 (en) 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer
SG10201506658TA SG10201506658TA (en) 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012012647A SG178814A1 (en) 2007-02-26 2008-02-26 Utility of b-raf dna mutation in diagnosis and treatment of cancer

Country Status (7)

Country Link
US (2) US9556491B2 (en)
EP (1) EP2129791A4 (en)
JP (1) JP2010528585A (en)
AU (2) AU2008221468A1 (en)
CA (1) CA2713303A1 (en)
SG (2) SG178814A1 (en)
WO (1) WO2008106453A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04002810A (en) * 2001-09-26 2005-06-06 Rheogene Holdings Inc Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof.
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc System and method for determining individualized medical intervention for a disease state
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
CN102232117A (en) * 2008-10-14 2011-11-02 卡里斯Mpi公司 Gene targets and protein targets of gene expression to delineate tumor type biomarker patterns and signature sets
DK3301446T3 (en) * 2009-02-11 2020-06-29 Caris Mpi Inc Molecular tumor profiling
CN101487051B (en) * 2009-02-24 2011-07-20 广州益善生物技术有限公司 Detecting probe and liquid phase chip for BRAF gene mutation and detecting method thereof
US20110177512A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Method for assuring amplification of an abnormal nucleic acid in a sample
KR101825117B1 (en) * 2010-02-01 2018-02-06 주식회사 파나진 Methods and kits for the BRAF mutant detection using PNA mediated Real-time PCR clamping
KR101312241B1 (en) 2010-04-27 2013-09-27 사회복지법인 삼성생명공익재단 Method of detecting gene mutation using a blocking primer
CN102959091A (en) * 2010-06-30 2013-03-06 三菱化学美迪恩斯株式会社 Highly sensitive mutated gene detection method
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
CN103748236B (en) 2011-04-15 2018-12-25 约翰·霍普金斯大学 Safe sequencing system
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
WO2013190089A1 (en) * 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
PL2912468T3 (en) 2012-10-29 2019-04-30 Univ Johns Hopkins Papanicolaou test for ovarian and endometrial cancers
US10373149B1 (en) 2012-11-12 2019-08-06 Square, Inc. Secure data entry using a card reader with minimal display and input capabilities having a display
WO2014135669A1 (en) * 2013-03-08 2014-09-12 Roche Diagnostics Gmbh Egfr mutation blood testing
EP3058103A4 (en) * 2013-10-19 2017-05-17 Trovagene, Inc. Detecting and monitoring mutations in histiocytosis
US20160115556A1 (en) * 2013-10-19 2016-04-28 Trovagene, Inc. Detecting mutations in disease over time
EP3058099A4 (en) * 2013-10-19 2017-06-28 TrovaGene, Inc. Detecting mutations in disease over time
US20150132256A1 (en) * 2013-10-19 2015-05-14 Trovagene, Inc. Detecting and monitoring mutations in histiocytosis
CN104762371B (en) 2014-01-07 2021-03-09 三星电子株式会社 Biomarkers for predicting or monitoring the efficacy of c-Met inhibitors
US20150344957A1 (en) * 2014-06-01 2015-12-03 Trovagene, Inc. Monitoring treatment of histiocytosis with vemurafenib and dabrafenib
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
RS59710B1 (en) * 2014-08-07 2020-01-31 Pharmassist Ltd Method of determining pik3ca mutational status in a sample
KR20160037666A (en) 2014-09-29 2016-04-06 삼성전자주식회사 Prediction of Effect of a c-Met Inhibitor using mutation of KRAS or BRAF
WO2017014177A1 (en) * 2015-07-17 2017-01-26 凸版印刷株式会社 Method for evaluating health state and method for predicting long-term efficacy of anticancer agent
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
MX2020001575A (en) 2017-08-07 2020-11-18 Univ Johns Hopkins MATERIALS AND METHODS TO EVALUATE AND TREAT CANCER.
US20220073977A1 (en) 2020-02-14 2022-03-10 The Johns Hopkins University Methods and materials for assessing nucleic acids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014793A1 (en) 1995-10-20 1997-04-24 Trustees Of Boston University Nucleic acid clamps
US20040146879A1 (en) * 1998-08-31 2004-07-29 Bayer Healthcare Llc Novel human genes and gene expression products
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
EP2395101B1 (en) * 2005-05-02 2013-11-13 University of Southern California DNA methylation markers associated with the CpG island methylator phenotype (cimp) in human colorectal cancer

Also Published As

Publication number Publication date
EP2129791A4 (en) 2010-07-28
AU2008221468A1 (en) 2008-09-04
WO2008106453A2 (en) 2008-09-04
EP2129791A2 (en) 2009-12-09
CA2713303A1 (en) 2008-09-04
US9567640B2 (en) 2017-02-14
AU2014204427A1 (en) 2014-07-31
SG178814A1 (en) 2012-03-29
US20080268449A1 (en) 2008-10-30
WO2008106453A3 (en) 2008-11-06
US20120295258A1 (en) 2012-11-22
US9556491B2 (en) 2017-01-31
JP2010528585A (en) 2010-08-26

Similar Documents

Publication Publication Date Title
SG10201506658TA (en) Utility of b-raf dna mutation in diagnosis and treatment of cancer
IL208518A0 (en) Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
SI2412828T1 (en) K-ras and B-raf mutations and anti-EGFr antibody therapy
PT3130923T (en) Therapeutic and diagnostic methods relating to cancer stem cells
ZA200907426B (en) Use of low temperature and/or low PH in cell culture
IL204566A0 (en) Adherent cells from adipose or placeta tissues and use thereof in therapy
LT2999791T (en) Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer
PT2162118T (en) Porous microspheres and their use in therapy
EP2291553A4 (en) Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
EP2142673A4 (en) Nucleic acid enzymes and complexes and methods for their use
GB0718250D0 (en) Improvements in and relating to reaction apparatus
PT2614832T (en) Diagnosis and treatment of preeclampsia
SG10201604988YA (en) Methods and compositions for diagnostic use in cancer patients
IL205864A (en) Methods of analysis of circulating melanoma cells in patients with metastatic melanoma
PL2173337T3 (en) Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin
IL208579A0 (en) Methods and use of inducing a poptosis in cancer cells
EP2012798A4 (en) Use of inositol-tripyrophosphate in treating tumors and diseases
GB0820397D0 (en) Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
HK1138889A (en) Utility of b-raf dna mutation in diagnosis and treatment of cancer
EP2115127A4 (en) Methods and compositions for improving the health of cells in culture
EP1973398A4 (en) Use of inositol-tripyrophosphate in treating tumors and diseases
GB0818663D0 (en) Gene regulation and its use in therapy
HK1152244A (en) Methods and use of inducing apoptosis in cancer cells
GB2454875B (en) Parenteral composition for use in treatment of cancer and method of manufacture thereof
GB0818032D0 (en) Improvements in and relating to analysis of mixed source dna profiles